AUTHOR INDEX

Volume 28, 1994

Abrams, R. A., 1017, 1047
Adelson, J., 105
Ahern, V., 867
Aizawa, O., 1143
Alden, M. E., 945
Alexander, III, E., 1229
Allen, B. J., 1183
Alth, G., 463
American Association of Neurological Surgeons, Task Force on Stereotactic Radiosurgery, 527
American Society for Therapeutic Radiology and Oncology, Task Force on Stereotactic Radiosurgery, 527
Amichetti, 163
Anderson, L., 971
Anikin, V. A., 703
Anisuzzaman, A. K. M., 1203
Antoniades, J., 783
Aref, A., 467
Armour, E. P., 171
Arnold, A., 355
Arterbery, V. E., 985
Asbell, S. O., 39
Ashley, S., 405
Auger, E. A., 179
Ayoub, J., 355
Ayyangar, K. M., 979

Baggs, R., 621
Bagshaw, M. A., 17, 23, 151
Bailey, M. Q., 1079, 1089
Bar-Deroma, R., 749
Barker, E. A., 395
Barnes, P. D., 1229
Barraclough, B., 867
Barth, R. F., 1057, 1059, 1079, 1089, 1203
Bartholomew, R. M., 505
Bauer-Kirpes, B., 481
Beard, C. J., 303
Beattie, E. J., 719
Beck-Bornholdt, H.-P., 583
Bedrosian, C. L., 213
Begnozzi, L., 515
Behar, R. A., 221
Belkacemi, Y., 343
Ben-Yosef, R., 151
Benassi, M., 515
Benson, R., 67
Berger, A., 189
Bergin, C. J., 93
Berner, B., 247
Bernstein, M. J., 373
Berson, A. M., 719
Bezwoda, W. R., 613
Bitar, N., 105
Bjärngard, B. E., 749
Bjordal, K., 847
Bjurstrom, T., 213
Blue, T. E., 1157
Bohndorf, W., 387
Bonner, J. A., 363
Bortfeld, T. R., 723
Bosch, C., 867
Bourland, J. D., 471
Bova, F. J., 523, 803, 1047
Boxwala, A. A., 1009
Boyages, J., 867
Boyer, A. L., 723
Braban, L. E., 563
Brabbins, D., 67
Brada, M., 405, 553
Brahme, A., 785
Braverman, I. M., 829
Brenner, D. J., 1039
Brewer, Y., 1251
Brezovich, I. A., 1025
Britten, R. A., 913
Brizel, D. M., 213
Bronk, M., 105
Brossard, S., 1135
Brown, J. M., 145, 661
Browning, P. G., 913
Brugger, R. M., 1149
Buchholz, T. A., 784, 1135
Bünemann, C., 583
Bünemann, H., 583
Burman, C. M., 55
Burnison, C. M., 47
Buswell, L., 201
Butler, E. B., 247, 263

Caplan, R. J., 47
Carlens, P., 1235
Carpino, S., 515
Carroll, P. R., 33
Castro, J. R., 257
Chang, L.-F. L., 589
Chapman, D. S., 55
Charles, H. C., 415
Chauvet, B., 1251
Chen, E. Y., 661
Chen, P. Y., 171
Chiatti, L., 515
Chobe, R. J., 101
Choy, D., 457
Clark, B. G., 1243
Cleary, S. F., 77
Cline, J. M., 649, 921
Coderre, J. A., 1067, 1079, 1107, 1167
Coffey, R. J., 797
Cogen, P. H., 425
Coleman, C. N., 201, 303, 321
Coleman, L., 33
Contreras, L., 891
Cooper, D. L., 829
Corrao, A., 749
Corry, P. M., 171
Cosmatis, D., 201
Coughlin, C. T., 1029
Cowan, K. H., 395
Cox, R. S., 17, 23, 85, 93, 229, 327
Coy, P., 355
Craven, T. E., 349
Curran, B. H., 1001
Curran, Jr., W. J., 549

D'Angelo, T., 395
Dale, J., 613
Davis, L. W., 47
Deasy, J., 784
DeHaan, C. E., 1099
Denham, J. W., 731
Deshmukh, A., 101
Deshpande, D. D., 499
Dewhirst, M. W., 415
Dillehay, L. E., 505
Dinshaw, K. A., 499
Diokno, A., 67
Dixon, P., 355
Dodge, R. K., 213, 415
Dominique, C., 343
Donaldson, S. S., 77, 85
Dorie, M. J., 145
Dorn, III, R. V., 1189
Dover, J. D., 935
Dunbar, S. F., 1229
Dutreix, A., 285

Eapen, L., 531
Earle, J. D., 207
Edmundson, G., 67
Edwards, M. S. B., 425
Eifel, P. J., 113
Eisert, D., 523
El Kattan, Y., 1113
El-Naggar, A. K., 821
Elyan, S., 405
Engin, K., 935
Engler, M. J., 1001
Epenetos, A. A., 1257
Epstein, J. B., 693
Erickson, B. A., 905
Evans, M. D. C., 1243
Evans, W. K., 355
Ezzell, G., 467

Fairbanks, R. K., 363
Febo, R., 1219
Fee, Jr., W. E., 221
Feld, R., 355
Feldman, A. M., 829
Félix-Faure, C., 1251
Fessenden, P., 151
Fine, R. L., 213
Finkelstein, J. N., 621
Fish, B. L., 883
Fisher, S. R., 213
Flick, M. B., 135
Flickinger, J. C., 797
Foley, J. F., 207
Fomin, S. D., 703
Fontanesi, J., 493
Foo, D.-L., 457
Fornander, T., 1235
Fowler, J., 784
Fowler, S., 445
Fraass, B. A., 277, 575
Fragomeni, R., 515
Freedman, A., 1067
Friedman, N. D., 829
Friedman, W. A., 803, 1047
Fuks, Z., 7, 55, 327, 985, 1219
Fulcrand, G., 1113
Fuller, B. G., 229

Gabel, D., 1175
Gahbauer, R. A., 1157
Garton, G., 67
Gash, D., 1067
Gauwitz, M. D., 821
Gavin, P. R., 1099
Gelman, R., 303
Gentile, F. P., 515
Georgiou, A., 811
Gerner, E. W., 891
Geyer, E., 189
Ghoshal, S., 335
Giaccia, A. J., 661
Gilbert, L., 395
Gildenberg, P., 247
Gindrey-Vie, B., 343
Glatstein, E., 315, 395
Glück, S., 877
Goel, R., 531
Goffinet, D. R., 151, 221, 251
Gonzalez, J., 67
Goodman, M. L., 797
Goodrich, A. L., 829
Goris, M. L., 119
Goudgaon, N. M., 1113
Grado, G. L., 439
Grant, III, W., 247
Greenberg, D. D., 1149
Gregg, D., 105
Griebenow, M. L., 1099
Griffin, T. W., 47, 1135
Grigsby, P. W., 451, 1271
Gunderson, L. L., 201
Gupta, B. D., 335
Gupta, N., 1157
Gyenes, G., 1235

Habermann, T. M., 363
Habrand, J.-L., 381
Hae-Sook, Y., 33
Hahn, G. M., 179
Halberg, F. E., 201
Hall, E. J., 1039

Hamilton, C. S., 731
Hamlet, S., 467
Hancock, S. L., 93
Hanks, G. E., 39, 201
Hanlon, A. L., 39
Hansen, J., 1067
Hao, Y., 563
Harari, P. M., 891
Haritz, D., 1175
Harrelson, J. M., 415
Harrison, L., 985
Harsh, IV, G. R., 797
Hartmann, G. H., 481
Harvey, J. C., 719
Haston, C. K., 633
Hatanaka, H., 1061
Hauptman, H. M., 1149
Hayhurst, E., 105
Hazuka, M. B., 575, 857
Healy, J. B., 554
Heilmann, H.-P., 583
Heimann, R., 55
Herman, M. G., 1017, 1047
Hill, R. P., 633
Hitchon, H. D., 935
Hodson, D. I., 355, 839
Holmes, T., 784
Holupka, E. J., 1229
Hong, W. K., 543
Hopewell, J. W., 1089, 1107
Hopkins, K. L., 93
Hoppe, R. T., 445
Horvath, J., 589
Hu, J.-P., 1149
Huang, A., 213
Hudgins, W. R., 797
Huiskamp, R., 1175

Inwards, C. Y., 363
Ito, H., 899
Ivanova, L. F., 703
Ivanov, V. N., 703

Jacky, J., 1135
James, S. J., 641
Janjan, N. A., 667, 773
Jindra, R. H., 463
Joel, D. D., 1067, 1167
Johnson, D. W., 101
Johnson, J. M., 741
Johnston, C. J., 621
Jones, G. W., 839
Jones, R., 1183
Joreskog, E., 1219

Kaasa, S., 847
Kacinski, B. M., 829
Kahler, D. L., 723
Kalifa, C., 381
Kallman, R. F., 761
Kantoff, P. W., 303
Kaplan, I. D., 17, 23, 257, 327
Kapp, D. S., 151, 189, 229
Kapp, K. S., 189
Kavanagh, B., 597
Keane, T. J., 557, 563
Kenan, P. D., 213
Khan, F. M., 741
Kharazi, A. I., 641
Kim, B. S., 711
Kim, G. E., 711
Kim, H., 373
Kim, M. W., 711
Kim, R. Y., 1025
Kim, W. H., 711
Kinsella, T. J., 891
Kiricuta, I. C., 387
Klein, E. E., 753
Kleinberg, L., 985
Kline, R., 523
Knox, S. J., 119, 445
Koestner, A., 1089
Koh, W.-J., 557
Kölbl, O., 387
Komaki, R., 899
Kondziolka, D., 797
Koong, A. C., 661
Kooy, H. M., 551, 1229
Koren, H., 463
Kostashuk, E., 355
Kraft, S. L., 1099
Krall, J. M., 39
Krook, J. E., 207
Kucik, N. A., 373
Kun, L., 493
Kuruvilla, A., 101
Kutcher, G. J., 55, 327, 1219
Kuten, A., 613
Kvols, L. K., 207

Lai, P. P., 373
Lakier, R., 613
Lancaster, S. E., 784
Langlands, A., 867
Laramore, G. E., 47, 1135
Larson, D. A., 523, 797
Larsson, L. G., 1219
Laugier, A., 343
LaVigne, M. L., 277
Lawton, C. A., 883
Leavitt, D. D., 297
Lee, A. S., 661
Lee, H. K., 811
Lee, J. S., 543
Lee, J. T., 711
Leeper, D. B., 935
Lefkopoulos, D., 343
Leibel, S. A., 7, 55, 327, 1219
Leopold, K. A., 213, 415
Lesnikowski, Z., 1113
Leunens, G., 285
Levitt, M., 355
Li, D.-J., 935
Li, G. C., 425
Li, Z., 953
Lichter, A. S., 575, 857
Ling, C. C., 55, 971, 1219
Ling, S.-S., 589
Link, M. P., 77
Liotta, D. C., 1113
Liu, H. B., 1149, 1167
Livesey, J. C., 1135
Lo, Y.-C., 55
Lockett, M. A., 811
Loeffler, J. S., 523, 1229
Loh, J. J. K., 711
Lorenz, W. J., 481
LoSasso, T. J., 55, 1219
Lubinski, J. M., 641
Lunsford, L. D., 797
Lutz, W., 523

Ma, H.-K., 457
Macio, I., 105
Mackie, R., 784
Mackie, T. R., 1001
MacPhail, P., 613
Mageras, G. S., 1219
Mah, K., 563
Maity, A., 135
Mak, A. C., 597
Mak, J. Y., 425
Makinodan, T., 641
Mallesch, J. L., 1183
Maor, M. H., 47
Maples, W. J., 439
Marcus, Jr., R. B., 556
Markiewicz, D. A., 135
Marks, L. B., 553, 777
Maroun, J., 355
Marquez, C., 33, 445
Marquez, C. M., 425
Marschke, Jr., R. F., 439
Martel, M. K., 277, 575, 857
Martenson, Jr., J. A., 439
Martin, P. J., 221
Martin, W. D., 991
Martinez, A., 67, 171
Marzoni, A., 105
Mason, K. A., 667
Mason, W. P., 1001
Mastekaasa, A., 847
Masterson, M. E., 1219
Matalka, K. Z., 1079, 1089
Mayer, R. R., 505, 1017, 1047
McCarthy, W. H., 1183
McClenathan, J., 105
McCollough, K. P., 471
McComas, V., 263
McCunniff, A. J., 349
McEntee, M. C., 649
McGann, J. K., 119
McKenna, P. J., 207
McKenna, W. G., 135
McShan, D. L., 277
Medvedev, V. S., 703
Mehta, M., 523
Meigooni, A. S., 953
Melian, E., 55
Mendenhall, N. P., 556
Mendenhall, W. M., 556, 803, 1047
Menke, D., 145
Merino, M. J., 395
Messner, H. A., 877
Metcalfe, P. E., 731
Micca, P., 1107
Michaletz-Lorenz, M., 753
Milas, L., 899
Min, J. S., 711
Minchinton, A. I., 119
Mishra, S., 699, 719
Mishra, V., 953
Mivechi, N. F., 179
Moeschberger, M. L., 1079
Mohan, R., 55, 1219
Mohiuddin, M., 945
Molepo, J. M., 531
Monro, P., 405
Montpetit, V. A. J., 531
Moore, D. E., 1183
Moravek, J., 1113
Morris, G. M., 1107
Morris, M., 113
Morton, I. E., 913
Moulder, J. E., 883, 905
Mulkern, R. V., 1229
Murray, N., 355
Muschel, R. J., 135

Nagorney, D. M., 201
Nakagawa, Y., 1061, 1217
Nakamura, L. T., 641
Narayan, P., 33
Navvab, Z., 33
Negi, P. S., 335
Nehru, R. M., 499
Newcomb, C. H., 633
Ngan, H. Y. S., 457
Nigg, D. W., 1121
North Florida Pterygium Study Group, 101
Noyes, R. D., 201
Nseyo, U. O., 33

O'Brien, P. C., 683
Ochran, T. G., 667
Olds, W. W., 349
Oleson, J. R., 415
Omarov, A. A., 703
Orazem, J. P., 55
Ostwald, P. M., 731
Oswald, M. J., 113
Ota, D. M., 597
Otterson, M. F., 905
Owen, J. B., 39
Ozsahin, M., 343

Page, R. L., 415, 1029
Palta, J., 493, 523
Panella, T. J., 213
Papavasiliou, C., 605
Pareek, P. N., 1025
Park, Y.-M. K., 179
Paryani, S. B., 101
Patel, F. D., 335
Pater, J. L., 355
Pawlicki, T., 979
Payne, D. G., 355
Peacock, J. H., 913
Pene, F., 343
Perera, H., 953
Perez, C. A., 373, 451, 811
Petereit, D. G., 891
Peyton, W., 589
Phillips, M., 1135
Phillips, T. L., 257, 267, 325, 425, 1215
Pickart, M. A., 891
Pickett, B., 267
Pickuth, D., 405
Pierce, L. J., 395
Pilepich, M. V., 39

Pisch, J., 719
Pistenmaa, D. A., 315
Pla, C., 1243
Pollack, A., 821
Pollock, R., 773
Poon, P. Y., 563
Popovic, P., 531
Prados, M. D., 431
Prescott, D. M., 415
Prestidge, B. R., 17, 263
Prionas, S. D., 151
Prosnitz, L. R., 213, 777

Raaphorst, G. P., 531
Rajan, B., 405
Raleigh, J. A., 649, 921
Randall, M. E., 349
Ray, G. R., 105
Rebeiro, E., 773
Reboul, F., 1251
Rekacewicz, C., 381
Rey, A., 381
Rich, T. A., 597
Richmond, R. C., 1029
Risler, R., 1135
Roa, W. H. Y., 857
Roach, III, M., 33, 267
Roberts, J., 839
Roberts, J. A., 277
Rockwell, S., 127
Rofstad, E. K., 1079
Roh, J. K., 711
Rojan, B., 553
Roman, T. N., 1243
Romsdahl, M. M., 597
Rong, F.-G., 1203
Roos, D. E., 683
Rorer, D. C., 1149
Rosenman, J. G., 1009
Rosenthal, D., 839
Rosenthal, D. I., 315
Rosenthal, S. A., 267
Rosner, G. L., 921
Rousseau, P., 381
Rowlinson-Busza, G., 1257
Roy, J., 971, 985
Rubin, P., 1, 3, 333, 561, 621, 795, 1055, 1067
Ruifrok, A. C. C., 667
Russell, K. J., 47
Rutqvist, L. E., 1235

Sadura, A., 355
Sahoo, N., 971
Sailor, T., 1001
Salter, M. M., 1025
Sandler, H. M., 857
Sarna, S. K., 905
Sarrazin, D., 381
Saw, C. B., 979
Schell, M. C., 551
Schenk, G. M., 463
Schewe, K., 523
Schilling, P. J., 1267
Schinazi, R. F., 1113
Schlienger, M., 343
Schoeppel, S., 101
Schoeppel, S. L., 277
Schray, M., 67
Schultheiss, T. E., 597
Schultz, C., 523
Schutt, A. J., 207, 439
Schwartz, L. H., 343
Scidmore, N. S., 93
Scott, W. P., 101
Selles, W. D., 1001
Seong, J. S., 711
Serago, C. F., 481
Shah, K. J., 991
Shalev, S., 1043
Sham, J., 457
Shao, Y., 505
Sharma, S. C., 335
Shaw, D., 263
Shaw, E. G., 523, 797
Shin, H. S., 711
Shrieve, D. C., 1251
Shrivastava, S. K., 499
Sigmon, W. R., 349
Slatkin, D. N., 1167
Smith, T. L., 113
Smitt, M. C., 251
Sneed, P. K., 425, 797
Snook D., 1257
Soloway, A. H., 1057, 1059, 1079, 1203
Song, S., 505
Sostman, H. D., 415
Souhami, L., 1243
Speiser, B. L., 781
Spencer, D., 613
Spencer, S. A., 1025
St. Clair, W. H., 349
Staubus, A. E., 1079
Stein, M. E., 613
Steinberg, S. M., 395
Stening, W. A., 1183
Sternick, E. S., 1001
Stewart, D. J., 531
Stewart, J. R., 297
Strickler, J. G., 363
Stromberg, J., 67
Stuecklschweiger, G., 189
Su, J., 363
Suh, C. O., 711
Sutherland, W. R., 119
Swartz, C. D., 1099

Tadros, A., 839
Tarbell, N. J., 1229
Taulelle, M., 1251
Taylor, J. M. G., 641
Taylor, K. D., 531
Taylor, M., 753
Taylor, M. E., 47
Ten Haken, R. K., 575
Terrier-Lacombe, M.-J., 381
Terry, N. H. A., 821
Thames, H. D., 667
Thistlethwaite, A. J., 935
Thomas, G. M., 547
Thomas, Jr., C., 557
Thoms, Jr., W. W., 113
Thornton, A. F., 857
Thorson, B., 839
Thrall, D. E., 415, 649, 921
Tjarks, W., 1203
Touboul, E., 343
Traish, D., 405
Trembly, B. S., 673
Tsai, J.-S., 1001
Tschetter, L. K., 207
Tsirakis, B., 1219
Tucker, J. A., 415
Tupchong, L., 935
Turrisi, A. T., 575, 857
Twito, D. I., 207

Ullas, G., 1113
Umfleet, W., 753
Unni, K. K., 363
Urba, S., 857
Uzal, C., 343

Valdagni, R., 163
Van Dam, J., 285
Van der Schueren, E., 285
Van Dyk, J., 563, 633, 877
van Herk, M., 1229
Verhey, L., 267
Verma, A. K., 891
Vest, M. L., 451
Vikram, B., 699
Vincent, P., 1251
Viswanathan, P. S., 499
Vitu-Loas, L., 343
von Eschenbach, A. C., 821
Vtyurin, B. M., 703

Waldron, T. J., 723
Wall, T. J., 1267
Waller, E. K., 119
Wallner, K., 971, 985
Wambersie, A., 1157
Wang, Z., 171
Wara, W. M., 431
Warenius, H. M., 913
Wasserman, T. H., 373
Wazer, D. E., 1001
Weiner, R., 797
Wells, Jr., J. W., 101
Whitehouse, E. M., 1107
Whitmore, Jr., W. F., 7
Wieand, H. S., 207
Wierzbicki, R., 355
Wilbur, D. S., 1135
Wilder, R. B., 119
Wilkie, D. A., 1089
Williams, J. R., 505
Williamson, J. F., 953
Willman, K. Y., 85
Willner, J., 387
Willson, K., 683
Wilson, J. F., 523
Wilson, K., 355
Wilson, L. D., 829
Wiseberg, J. A., 55
Wolf, G. T., 857
Womack, T., 213
Wong, F. L. W., 693
Wong, P. T. T., 531
Wong, R. L. C., 457
Wong, T. Z., 673
Woo, S., 247
Wooding, Jr., T. S., 1067
Wootton, P., 1135
Wright, J., 683
Wu, A., 979
Wu, P.-M., 457
Würschmidt, F., 583
Wyzlic, I. M., 1203

Yeung, D., 493

Zagars, G. K., 821
Zaghloul, M. S., 783
Zee, B., 355
Zelefsky, M. J., 7, 55, 327, 985
Zhang, Y.-G., 505
Zincke, H., 67
Zink, S., 47
Zoeller, D., 753

SUBJECT INDEX

Volume 28, 1994

A

Absorbable mesh, 719
Absorbed dose, 1143
Accuracy, 481
Acoustic, 803
Acute effect, 667
Adjuvant chemotherapy, 829
Adolescents, 991
Advanced stage, 67
Air gap, 741
α-difluoromethylornithine (DFMO), 891
Amphotericin, 883
Anal cancer, 189
Analysis
  Cost benefit, 773
  Image, 505
  Video image, 921
Antenna
  Insulated, 673
  Theory, 673
Anthropomorphic phantom, 731
Antibody, 1257
ARRO 1992 survey, 1267
Assay(s)
  Microcolony, 667
  Predictive, 415
Asymmetric jaws, 753

B

Beam
  Epithermal neutron, 1149
  Photon, 979
Beta ray, 101
Bile duct cancer, 945
  Brachytherapy combined modality treatment, 945
Biopsy of prostate, 17
Bladder and rectal dose, 277
Blood–brain barrier, 1067
Bone, 363
Bone-marrow
  Transplant, 883
  Transplantation, 343
Boron, 1061, 1113, 1121, 1135, 1143
  Determination techniques, 1175
  Neutron capture therapy (BNCT), 1067, 1079, 1089, 1099, 1107, 1121, 1135, 1143, 1149, 1157, 1175, 1183, 1189, 1203
Boronated
  Amino acids, 1203
  Nucleosides, 1203
  Nucleotides, 1203
  Peptides, 1203
Boronophenylalanine, 1089
Brachytherapy, 113, 151, 171, 189, 247, 263, 335, 499, 699, 703, 953, 971, 985
  Combined modality treatment of bile duct cancer, 945
  High dose rate, 589, 1243
  Interstitial, 221
  Intraluminal, 711
  Pulsed, 667
Brain, 1089, 1099
  Neoplasm, 431
  Tumor(s), 1167, 531
Breast, 753
  Treatment, 297
Breast cancer, 285, 387, 395
  Early, 1235
  Locally advanced, 867
  Recurrent, 463
Brookhaven Medical Research Reactor (BMRR), 1149, 1167
BSH, 1107
  Biodistribution, 1175
  Pharmacokinetics, 1175
  Toxicology, 1175
Bulky endocervical cancer, 113
Busulfan, 883

C

Calculation of dose, 749
Californium-252, 703
Caloric restriction, 641
Cancer, 891
  Anal, 189
  Bile duct, 945
  Brachytherapy combined modality treatment of bile duct, 945
  Breast, 285, 387, 395
  Bulky endocervical, 113
  Cervical, 451
  Cervix, 335
  Early breast, 1235
  Endobronchial, 589
  Gastrointestinal, 439
  Head and neck, 699, 847, 1025
  Intraductal, 105
  Limited stage small cell lung, 355
  Locally advanced breast, 867
  Lung, 575, 589
  Nonsmall cell lung, 583, 1251
  Pancreatic, 207
  Pediatric, 85
  Prostate, 33, 39, 47, 151, 263, 303, 821, 1029
  Recurrent cervical, 451
  Rectal, 597
  Recurrent breast, 463
Canine(s), 415
  Tumors, 649
Capture therapy, 1061
Carbogen, 145
Carcinoma(s)
  Cervical, 457
  Cervix, 277, 499, 1243
  Colorectal, 349
  Ductal *in situ*, 105
  Endometrial, 349
  In situ (CIS), 251
  Metastatic gastric, 711
  Nasopharyngeal, 991
  Prostate, 7, 55, 67
  Prostatic, 23, 985
  Squamous cell, 213, 221
Cardiovascular disease, 1235
Cataract incidence, 343
CCI-103F, 649
Cell lines
  Human, 913
  Human myeloma, 877
C-erb B-2 amplification, 395
Cervical cancer, 451
  Recurrent, 451
Cervical carcinoma, 457
Cervix
  Cancer, 335
  Carcinoma, 277, 499, 1243
Chelate, 1257
Chemotherapy, 77, 355, 363, 431, 583, 683, 867
  Adjuvant, 829
  Concurrent, 213
Children, 381
CIS, 251
Cis-DDP, 899
Cisplatin, 531, 1251
  Plus irradiation, 761
Classical, 613
Clonogenic myeloma progenitors, 877
Coaxial sleeve, 673
Collimator(s), 1167
  Multileaf, 723
Colon epithelium, 899
Colorectal carcinoma, 349
Combined modality(ies), 761, 945, 1029
  Therapy, 77, 127, 563, 683, 1251
Compensation, 723
Complications, 113, 597, 1243
  Split course, 349
Compression of spinal cord, 605
Computed tomography, 277
Computer
  Control, 1219
  Model, 673
Computerized tomography (CT), 93
  Planning, 731
Concomitant chemoradiotherapy, 1251
Concurrent
  Chemotherapy, 213
  Radiochemotherapy, 1243
Conformal, 471
  Radiotherapy, 1219
  Therapy, 723
Conformal three-dimensional (3-D)
  Radiation therapy, 55
  Radiotherapy, 267
Conservative surgery, 105
Control
  Computer, 1219
  Local, 7, 163
  Tumor, 113
Cord
  Spinal, 1107
  Vocal, 251
Coronary artery, 1235
Correction(s)
  Heterogeneity, 953
  Inhomogeneity, 731
Cost benefit analysis, 773
Cutaneous T-cell lymphoma, 829
Cyclin B, 135
Cyclophosphamide, 829

Cyclosporine, 883
Cytokines, 1029

D

Deoxyribonucleic acid (DNA), 821
Diagnostic imaging, 1229
Diarrhea, 905
Disease
  Cardiovascular, 1235
  Hodgkin's, 77, 93, 445, 683
  Ischemic heart, 1235
  Pediatric Hodgkin's, 85
Distant metastases, 7, 387
Dogs, 1099
Dose(s), 945
  Absorbed, 1143
  Bladder and rectal, 277
  Calculation, 749
  Criteria, 1143
  Effect factor, 563
  Escalation, 55
  Heterogeneity, 971
  Intensity, 761
  Prescription, 1157
  Reference level, 515
  Total, 583
  Volume histogram(s), 515, 575
Dose rate
  High, 335
  High Ir-192, 711
  Instantaneous, 343
  Low, 335, 667
Dosimetry, 505, 953, 979
  In vivo, 285
  Neutron, 1149
  Thermoluminescence, 731
Doxorubicin, 829
Ductal carcinoma *in situ* (DCIS), 105

E

Early breast cancer, 1235
Eccentric core, 1143
Effect(s)
  Acute, 667
  Late, 85, 847
  Long-term, 1235
  Skin and eye radiation, 1089
Electrical control activity, 905
Electron
  Algorithm, 731
  Arc therapy, 297
  Beams, 741
  Boost, 1025
  Cone, 1025
ELISA, 649
Endemic Africa, 613
Endobronchial cancer, 589
Endometrial carcinoma, 349
Enhancement, 201
EORTC QLQ-C30, 847
Ependymoma, 381
Epidemic Kaposi's sarcoma, 613
Epithermal neutron beam, 1149
Errors of localization and treatment delivery, 493
Etanidazole, 119, 201
External beam
  Irradiation, 39
  Therapy, 979
Extracellular matrix, 621
Extracorporeal photoimmunotherapy, 829
Eye tumors, 101

F

Factor(s)
  Dose effect, 563
  Growth, 445, 621
  Heat shock transcription, 179
  Prognostic, 229
  Technical, 811
Fast neutron radiotherapy, 1135
Fibrosis, 621
Field
  Abuttment, 741
  Matching, 753
Filgrastim (G-CSF), 445
5-fluorouracil, 127, 439
Flow cytometry, 821
Follicular mucinosis, 829
Fraction spacing, 633
Fractionated
  Irradiation, 145
  Radiotherapy, 563
Fractionation, 343

G

Gastrointestinal cancer, 439
Gene induction, 661
Gentamicin, 883
Giant migrating contraction, 905
Glioblastoma, 1061
  Multiforme, 1175
Glioma, 247, 405, 1113, 1183
  Unverified, 405
Globe-sparing treatment, 857
Glottic, 251
Glucose regulated protein 78, 661
Growth, 85
  Factor, 445, 621
G2 delay, 135
Gynecologic implant, 277

H

Hazard rates, 39
Head and neck, 731, 891
  Cancer, 699, 847, 1025
  Neoplasms, 213
Heat resistance, 179
Heat shock proteins (HSP), 179, 425
  HSC 70, 179, 425
  HSP 28, 179
  HSP 70.1, 179
  HSP 70.2, 179
Heat shock transcription factor, 179
Heavy charged particles, 257
Height
  Impairment, 85
  Sitting, 85
  Standing, 85
Helium ions, 257
Hemoglobinopathy, 605
Heterogeneity
  Corrections, 953
  Dose, 971
High dose rate (HDR), 171, 247, 335
  Brachytherapy, 589, 1243
  Iridium-192, 711
HIV, 1113
Hodgkin's disease, 77, 93, 445, 683
Human(s), 415, 425
  Cell lines, 913
  Myeloma cell lines, 877
Hycanthone, 207
Hyperfractionation, 213, 431
Hyperglycemia, 935
Hyperthermia, 151, 163, 171, 415, 425, 673
  Interstitial, 189
  Sensitization, 935
Hypofractionation, 847
Hypoxia, 145, 661
  Markers, 649, 921
  Tumor, 649, 921
Hypoxic cell, 201

I

ICRU reference volume, 499
Image
  Analysis, 505
  Fusion, 1229
Imaging
  Diagnostic, 1229
  Magnetic resonance, 415
  On-line, 1017
  Portal, 1017
Immunohistochemistry, 921
Implant
  Gynecologic, 277
  Temporary, 719
  Vaginal-template, 457
Incidence of cataract, 343
Incomplete repair model, 667
Infradiaphragmatic, 683
Inhomogeneity correction, 731
In situ
  Carcinoma, 251
  Ductal carcinoma, 105
Instantaneous dose rate, 343
Insulated antenna, 673
Interleukin 1, 761
Interstitial, 673
  Brachytherapy, 221
  Hyperthermia, 189
  Iridium-192, 67
  RF, 151
Intracavitary, 673
  Therapy, 277
Intracerebral melanoma, 1079
Intracranial germ cell tumors, 229
Intraductal cancer, 105
Intraluminal brachytherapy, 711
Intraoperative radiotherapy, 201
Intrinsic cellular radiosensitivity, 913
In vivo, 667
  Dosimetry, 285
Iodine-125 implantation, 7
Iridium-192 (Ir-192), 719
  High dose rate, 711
  Interstitial, 67
Irradiation, 105, 451
  Cisplatin plus, 761
  External beam, 39
  Fractionated, 145
  Light, 463
  Prostate, 267
  Time, 1143
  Total body, 343, 1099
Ischemic heart disease, 1235
Isoeffect formulae, 633

K

Kinetics, 23, 891

L

L-arginine antagonists, 1029
Larynx, 251, 467
Late effects, 85, 847
Levamisole, 439
Light irradiation, 463
Limited stage small cell lung cancer, 355
Linac radiosurgery, 803
Linear accelerator, 471, 481, 1001
Local control, 7, 163
Localization, 1017
  Treatment delivery errors and, 493
Locally advanced breast cancer, 867
Long-term effects, 1235
Low dose
  Radiation, 641
  Rate (LDR), 335, 667
Lung, 621
  Radiation-induced damage, 633
Lung cancer, 575, 589
  Limited stage small cell, 355
  Nonsmall cell, 583, 1251
Lymph node(s)
  Metastases, 7
  Paraaortic, 451
  Supraclavicular, 387
Lymphoma, 363
  Cutaneous T-cell, 829
  NonHodgkin's, 119
Lymphomatoid papulosis, 829

M

Magnetic resonance imaging (MRI), 415
  Distortion, 1229
Magnetic resonance spectroscopy, 415
Malignant biliary obstruction, 711
Masses of extramedullary hemopoiesis, 605
Melanoma, 703, 1183
  Intracerebral, 1079
Meningioma, 257
Metastases, 797
  Distant, 7, 387
  Lymph node, 7
  Spinal, 229
Metastatic gastric carcinoma, 711
Mice, 899
Microcolony assay, 667
Microdosimetry, 1121
Mitomycin C, 127
MMC, 905
Model
  Computer, 673
  Incomplete repair, 667
  Nude rat, 1079
Modulation of mouse mammary tumor, 641
Monitor setting, 749
Monte Carlo simulation, 953
Morbidity, 811, 985, 1235
  Radiation, 55
Motility, 905
Multileaf collimators, 723
Multiple myeloma, 877
Mycosis fungoides, 829, 839
Myeloproliferative disorders, 605
Myelosuppression, 445

N

Nasopharyngeal carcinoma, 991
Nasopharynx, 699, 991
Nausea, 905
Neoplasm(s), 921
  Brain, 431
  Head and neck, 213
Nephropathy, 883
Neuroma, 803
Neutron(s), 47, 703, 913, 1061, 1121
  Dosimetry, 1149
  Epithermal beam, 1149
  Thermal, 1107
Neutron capture, 1135, 1143
  Therapy (NCT), 1113, 1167
Nicotinamide, 145
Nitroimidazoles, 921
Nodal recurrence, 387
NonHodgkin's lymphoma, 119
Nonsmall cell lung cancer (NSCLC), 583, 1251
Nonspecific dermatitis, 829
Normal bone marrow radiosensitivity, 877
Normal tissue
  Complication probability, 575
  Tolerance, 1099, 1157
  Toxicity, 583
Nucleosides, 1113
  Boronated, 1203
Nude rat model, 1079

O

On-line imaging, 1017
Open table-top device, 597
Oral mucositis, 693
  Prevention and treatment of, 693
Oral psoralen and total skin UVA light (PUVA), 829

P

Pancreatic cancer, 207
Paraaortic lymph nodes, 451
Paranasal sinus tumors, 857
Pathogenesis, 1107
p-Boronophenylalanine (BPA), 1183
Pediatric, 77
  Cancer, 85
  Hodgkin's disease, 85
Phantom, 1143
  Anthropomorphic, 731
Pharmacokinetics, 1183
  BSH, 1175
Photodynamic therapy, 463
Photon(s), 913
  Beam, 979
Pineal region tumors, 229
Planning
  Computerized tomography (CT), 731
  Three-dimensional (3-D) treatment, 857
  Treatment, 979, 1121, 1229
Platinum drugs, 1029
Ploidy, 821
Polyamines, 891
Polymerase chain reaction, 179
Portal imaging, 1017
Postirradiation, 17
Postoperative radiotherapy (XRT), 597
Precision, 481
Predictive assays, 415
Prevention and treatment of oral mucositis, 693
Primitive neuroectodermal tumors (PNET), 431
Probability
  Normal tissue complication, 575
  Tumor control, 515, 971
Prognosis, 387, 839
Prognostic factors, 229
  For prostate cancer, 33
Proliferation, 891
Prostate, 811
  Biopsy, 17
  Carcinoma, 7, 55, 67
  Irradiation, 267
  Specific antigen, 23, 55, 821
Prostate cancer, 33, 39, 47, 151, 263, 303, 821, 1029
  Prognostic factors for, 33
Prostatic carcinoma, 23, 985
Protein(s)
  Glucose regulated (78), 661
  Heat shock, 179, 425
  Over-expression, 395
Pterygium, 101
Pulsed brachytherapy, 667

Q

Quality assurance, 285, 773, 1001
Quality of life, 847
Questionnaires, 847

R

Racetrack microtron, 1219
Radiation, 127, 163, 531, 621, 839, 883, 891, 899, 945, 1029
  Induced lung damage, 633
  Low dose, 641
  Morbidity, 55
  Pneumonitis, 563
  Sensitizer, 201, 207
  Sickness, 905
  Skin and eye effects, 1089
  Sources, 703
Radiation therapy, 7, 85, 277, 285, 303, 373, 381, 431, 445, 467, 613, 683, 693, 811, 821, 857, 979
  Three-dimensional conformal, 55
  Total skin electron beam, 829
Radioimmunoglobulin therapy, 505
Radioimmunotherapy, 119
Radiosensitivity, 613
  Intrinsic cellular, 913
  Normal bone marrow, 877
Radiosurgery, 523, 797, 803
  Linac, 803
  Stereotactic, 471, 481, 493, 1229
Radiotherapy, 47, 67, 77, 113, 251, 257, 355, 363, 405, 583, 605, 773, 847, 867, 991, 1017, 1235, 1251
  Conformal, 1219
  Fast neutron, 1135
  Fractionated, 563
  Intraoperative, 201
  Machine, 1219
  Postoperative, 597
  Stereotactic, 1001, 1229
  Three-dimensional (3-D) conformal, 267
  Treatment planning, 515
Randomized trial, 207
Rat, 1167
  9L gliosarcoma, 1067
Rate
  High dose, 171, 247, 335
  Low dose, 335
  Relapse, 303

RBE, 913
Rectal cancer, 597
Recurrent
  Breast cancer, 463
  Cervical cancer, 451
Reference dose level, 515
Relapse, 303
Review, 1189

S

Sarcoma(s)
  Epidemic Kaposi's, 613
  Soft tissue, 415
Schedule dependence, 761
Sequelae, 163
Shaped field, 471
Silicon diode measurements, 953
Sitting height, 85
Skin, 1099
  Eye radiation effects, 1089
Soft tissue sarcomas, 415
Solid tumors in mice, 127
Sources of radiation, 703
Spinal cord, 1107
  Compression, 605
Spinal metastases, 229
Spleen, 93
Splenomegaly, 93
Split course complications, 349
Spontaneous fracture, 605
Squamous, 891
  Cell carcinoma(s), 213, 221
SR 2508, 201
SR 4233, 119, 145
Staging, 839
  Laparotomy, 683
Standing height, 85
Static field, 471
Stereotactic, 247, 797
  Radiosurgery, 471, 481, 493, 1229
  Radiotherapy, 1001, 1229
Strontium-90, 101
Subdiaphragmatic, 683
Supraclavicular lymph nodes, 387
Suprasellar tumors, 229
Surgery, 303
  Conservative, 105
Survival, 17, 163, 839
Swallowing, 467

T

Technical factors, 811
Techniques
  Boron determination, 1175
  Treatment, 753
Temporary implant, 719
Testicular seminoma, 373
Thalassemic osteoarthropathy, 605
Therapeutic gain, 761
Therapy monitoring, 415
Therapy, 1143
  Boron neutron capture, 1067, 1079, 1089, 1099, 1107, 1121, 1135, 1143, 1149, 1157, 1175, 1183, 1189, 1203
  Capture, 1061
  Combined modality, 77, 127, 563, 683, 1251
  Conformal, 723
  Electron arc, 297
  External beam, 979
  Intracavitary, 277
  Neutron capture, 1113
  Photodynamic, 463
  Radiation, 7, 85, 277, 285, 303, 373, 381, 431, 445, 467, 613, 683, 693, 811, 821, 857, 979
  Radioimmunoglobulin, 505
  Total skin electron beam radiation, 829
Thermal
  Distributions, 189
  Neutrons, 1107
Thermoluminescence dosimetry, 731
Thermometry, 151
Thermotolerance, 171, 425
Three-dimensional (3-D)
  Plans, 1009
  Reconstruction image processing, 1009
  Treatment planning, 575, 857
Three-dimensional (3-D) conformal
  Radiation therapy, 55
  Radiotherapy, 267
Tirapazamine, 145
Tissue concentrations, 531
Tomography
  Computed, 277
  Computerized, 93
Tonsil, 221
Total
  Body irradiation, 343, 1099
  Dose, 583
  Skin electron beam radiation therapy, 829
Toxicity of normal tissue, 583
Transplantation of bone-marrow, 343
Treatment planning, 1121, 1229
  Radiotherapy, 515
  Three-dimensional (3-D), 575, 857
Treatment
  Breast, 297
  Globe-sparing, 857
  Techniques, 753
  Time, 1157
  Volume, 499
TRIGA-II, 1143
Tumor(s)
  Brain, 531, 1167
  Canine, 649
  Eye, 101
  Hypoxia, 649, 921
  Infiltrating lymphocytes, 641
  Intracranial germ cell, 229
  Markers, 33
  Modulation of mouse mammary, 641
  Paranasal sinus, 857
  Perfusion, 1029
  pH, 935
  Pineal region, 229
  Primitive neuroectodermal, 431
  Solid in mice, 127
  Suprasellar, 229
Tumor control, 113
  Probability (TCP), 515, 971
2-nitroimidazoles, 649

U

Ultrasound guidance, 263
Unverified glioma, 405

V

Vaginal
  Stenosis, 457
  Template implant, 457
Video image analysis, 921
Vietnam, 773
Vocal cord, 251
Volume
  ICRU reference, 499
  Treatment, 499
Vomiting, 905

W

Warm-water hyperthermia system, 189
WR-2721, 899

X

X rays, 723
Xenograft, 1257

Y

Ytterbium-169, 953
Yttrium, 1257